AI-generated analysis. Always verify with the original filing.
NuCana plc reported fourth quarter and year-end 2025 financial results, with a Q4 net loss of £2.5 million and full-year net loss of £29.4 million, alongside £24.3 million in cash and cash equivalents expected to fund operations into 2029. The company highlighted clinical activity of NUC-7738 in PD-1 inhibitor-resistant melanoma and outlined 2026 milestones including Phase 2 data and FDA guidance.
Event Type
Disclosure
Voluntary
Variant
6-K
Current Report on Form 6-K
| Metric | Value | Basis |
|---|---|---|
| Net Loss Q4 | $-2.50 | GAAP |
| Basic and Diluted Loss per Ordinary Share Q4 | $0.00 | GAAP |
| Net Loss FY | $-29.40 | GAAP |
| Basic and Diluted Loss per Ordinary Share FY | $0.00 | GAAP |
Theresa Bruce